354 followers
Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment f... https://t.co/dCkS3ewHfW
Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment f... https://t.co/dCkS3ewHfW
《短報》 【肺がん:一次治療】「シスプラチン+ドセタキセル+アバスチン」治療を選択した場合の奏効率74.5%、無増悪生存期間9.0ヵ月、生存期間27.5ヵ月。日本のPhase2試験「TORG1016」の結果より〔BMC Cancer〕。 https://t.co/c0PuMtnKvH